Inozyme Pharma Inc Investor and Analyst Event (Virtual) Transcript
Good morning and thank you for joining us for the Inozyme February 2023 virtual investor and analyst event. Today's remarks will be followed by a question-and-answer session with the management team and key opinion leaders, please dial in via telephone to participate.
Before we begin our formal remarks, I would like to point you to our forward-looking statements disclaimer.
I would now like to turn the event over to Axel Bolte, Co-Founder, President, and Chief Executive Officer of Inozyme Pharma.
Good morning, and welcome to our first investor and analyst event from our labs in Boston. Inozyme has made tremendous progress over the past year. We are developing a potential first-in-class therapy for ENPP1 Deficiency and ABCC6 Deficiency, two rare mineralization disorders, where patients suffer severely with up to 50% mortality and have no approved therapeutic options.
With INZ-701, we have a Phase 3-ready asset that has shown a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
